Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 7Ovarian Neoplasms 6Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Urogenital Neoplasms 3Stomach Neoplasms 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Rectal Neoplasms 2Neuroblastoma 2Multiple Myeloma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1

Interventions

Specimen Handling 6Human Papillomavirus DNA Tests 4Colposcopy 4Papillomavirus Vaccines 2Human Papillomavirus Recombinant Vaccine nonavalent 2Cisplatin 2Carboplatin 2toripalimab 1fludarabine phosphate 1fludarabine 1epigallocatechin gallate 1aldesleukin 1Transurethral Resection of Prostate 1Standing Orders 1Respiratory Function Tests 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1Prochlorperazine 1Positron-Emission Tomography 1Platinum 1Ondansetron 1O(6)-codeine methyl ether 1Methods 1Meperidine 1Magnetic Resonance Imaging 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillomavirus Infections × aldesleukin × 90 days × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡